Live tape
Top 8, mentions 7d9,390TSLA1,985 mentions▲ +0.05GOOGL1,524 mentions▲ +0.04NVDA1,143 mentions▲ +0.07CRWV1,134 mentions▲ +0.03SPCX1,019 mentions▲ +0.07QQQ993 mentions▲ +0.04META796 mentions▲ +0.05NBIS796 mentions▲ +0.05

Equity · Healthcare

PTGX

NASDAQ

Protagonist Therapeutics, Inc.

$141 −0.70% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 29, 2026
Price · Chart
25 sessions
$155 $135 25 Aug 29 Sep

The line runs $151 on 25 August through $141 on 29 September, on a scale from $135 to $155. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 25 sessions, 25 Aug – 29 Sep 2026
Market cap $9.1B
P/E (TTM) 136.9
52-week range $64 – $151
Avg volume 52.1K

as of Sep 29, 2026

PTGX insider trades

SEC Form 4

PTGX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 21 November 2025.

Date Insider Type Shares Value
17 Nov 2025 MOLINA ARTURO MD Chief Medical Officer Sell 2,712 $230K
10 Oct 2025 Waddill William D. Sell 12,000 $979K
22 Sep 2025 Waddill William D. Sell 4,000 $257K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
21 Nov 2025 PATEL DINESH V PH D President and CEO Gift 440
10 Oct 2025 Waddill William D. Option exercise 12,000 $84K
16 Sep 2025 PATEL DINESH V PH D President and CEO Gift 620

PTGX reported financials

SEC EDGAR XBRL SEC EDGAR

PTGX reported revenue of $46.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$130.1M.

Figure Reported Period
Revenue $46.0M 31 Dec 2025 fiscal year
Net income −$130.1M 31 Dec 2025 fiscal year
Diluted EPS −$2.05 31 Dec 2025 fiscal year
Total assets $885.5M 30 Jun 2026 at period end
Total equity $841.5M 30 Jun 2026 at period end

PTGX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $2.29 —
31 Mar 2026 Q1 2026 $0.05 —
31 Dec 2025 FY 2025 −$2.05 —
30 Sep 2025 Q3 2025 −$0.62 —
30 Jun 2025 Q2 2025 −$0.55 —
31 Mar 2025 Q1 2025 −$0.19 —
31 Dec 2024 FY 2024 $4.23 —
30 Sep 2024 Q3 2024 −$0.54 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

PTGX institutional holders

SEC Form 13F SEC EDGAR

6 of the 45 institutional funds we track reported a PTGX position for the quarter ended 30 Jun 2026 — a combined $63.1M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Duquesne Family Office Added +30.8% shares 208,900 $25.6M
Fisher Asset Management Held (±25%) −2.0% shares 170,524 $20.9M
Marshall Wace Trimmed −82.6% shares 109,017 $13.4M
AQR Capital Management Held (±25%) +10.3% shares 13,096 $1.6M
Bridgewater Associates Added +75.7% shares 9,269 $1.1M
Balyasny Asset Management Trimmed −96.4% shares 3,598 $441K
Citadel Advisors Exited

PTGX fails-to-deliver

SEC CNS data SEC

On 15 Sep 2026, 3,133 shares of PTGX failed to deliver (about $463K).

Settlement date Shares failed Notional % of shares out
15 Sep 2026 3,133 $463K 0.005%
09 Sep 2026 28,995 $4.2M 0.045%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings